| Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript |
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer Theresa LaVallee - Chief Scientific & Development Officer Rosh Dias - Chief Medical Officer Sameer Goregaoker - Executive Vice President, Commercial Bryan McMichael - Chief Financial Officer Conference Call Participants Kripa Devarakonda - Truist Securities Brian Cheng - JPMorgan Mike Nedelcovych - TD Cowen Colleen Kusy - Baird Douglas Tsao - H.C. Wainwright Operator Good day and thank you for standing by. |
seekingalpha.com |
2025-05-13 02:46:56 |
Czytaj oryginał (ang.) |
| Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates |
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2025-05-12 22:30:43 |
Czytaj oryginał (ang.) |
| Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update |
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif. |
globenewswire.com |
2025-05-12 20:15:00 |
Czytaj oryginał (ang.) |
| Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 |
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. |
globenewswire.com |
2025-05-05 20:01:00 |
Czytaj oryginał (ang.) |
| Coherus to Participate in Upcoming Investor Conferences |
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming conferences: |
globenewswire.com |
2025-05-01 21:04:00 |
Czytaj oryginał (ang.) |
| Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 |
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif. |
globenewswire.com |
2025-04-28 14:10:00 |
Czytaj oryginał (ang.) |
| Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs |
Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hepatocellular carcinoma with a 17.2% complete response rate in phase 1 and is now in a phase 2 study. CHRS is still marketing Loqtorzi for nasopharyngeal carcinoma, with Q4'24 revenues of $7.5M representing 29% growth over the prior quarter. |
seekingalpha.com |
2025-04-17 09:53:33 |
Czytaj oryginał (ang.) |
| Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise |
– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – |
globenewswire.com |
2025-04-14 12:00:00 |
Czytaj oryginał (ang.) |
| Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting |
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois. |
globenewswire.com |
2025-03-25 18:30:00 |
Czytaj oryginał (ang.) |
| Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript |
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, Immuno-Oncology Marketing Theresa LaVallee - CDO Rosh Dias - CMO Bryan McMichael - CFO Conference Call Participants Srikripa Devarakonda - Truist Securities Yigal Nochomovitz - Citigroup Colleen Kusy - Baird Michael Nedelcovych - TD Cowen Brian Cheng - JPMorgan Douglas Tsao - H.C. Wainwright Operator Hello everyone and welcome to the Coherus Fourth Quarter Year Ending 2024 Financial Results Conference call. |
seekingalpha.com |
2025-03-10 22:52:24 |
Czytaj oryginał (ang.) |
| Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update |
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA® net revenue increased 62% year-over-year – – LOQTORZI® net revenue increased 29% quarter-over-quarter – |
globenewswire.com |
2025-03-10 18:12:00 |
Czytaj oryginał (ang.) |
| Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 |
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. |
globenewswire.com |
2025-03-03 10:30:00 |
Czytaj oryginał (ang.) |
| Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference |
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., Eastern time. A live audio webcast will be accessible through a link posted on the “Events and Presentations” section of the Coherus' investor website: https://investors.coherus.com/events-presentations . A replay of the presentation will be available on this same website for approximately 90 days. |
globenewswire.com |
2025-02-24 11:08:00 |
Czytaj oryginał (ang.) |
| Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 |
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - |
globenewswire.com |
2024-12-18 10:30:00 |
Czytaj oryginał (ang.) |
| Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development |
Coherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS holds $97.7 million in cash, $36.6 million in term loans, and $227.9 million in convertible notes, with $70.8 million in net revenues. CHRS is divesting their Udenyca franchise for $483.4 million, with potential milestone payments, following previous sales of Cimerli and Yusimry franchises. |
seekingalpha.com |
2024-12-16 20:08:57 |
Czytaj oryginał (ang.) |
| Why Is Coherus BioSciences Stock Trading Higher On Tuesday? |
On Tuesday, Coherus BioSciences, Inc. CHRS entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for up to $558.4 million. |
benzinga.com |
2024-12-03 11:34:10 |
Czytaj oryginał (ang.) |
| Coherus Management to Participate in the 2024 Citi Global Healthcare Conference |
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET. |
globenewswire.com |
2024-11-27 18:01:00 |
Czytaj oryginał (ang.) |
| Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript |
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-07 01:09:39 |
Czytaj oryginał (ang.) |
| Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates |
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2024-11-06 20:21:16 |
Czytaj oryginał (ang.) |
| Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update |
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA ® net revenue, quarter-over-quarter – |
globenewswire.com |
2024-11-06 18:01:00 |
Czytaj oryginał (ang.) |
| Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 |
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday, November 6, 2024. Starting at 5:00 p.m. ET on November 6, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. |
globenewswire.com |
2024-10-30 18:20:00 |
Czytaj oryginał (ang.) |
| Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript |
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Jami Taylor - Head of Investor Relations Dennis Lanfear - President and Chief Executive Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer Bryan McMichael - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. Douglas Tsao - H.C. Wainwright & Co. Billal Jahangiri - Truist Securities Michael Nedelcovych - TD Cowen Colleen Kusy - Robert W. |
seekingalpha.com |
2024-08-09 22:08:05 |
Czytaj oryginał (ang.) |
| Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates |
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.38 per share a year ago. |
zacks.com |
2024-08-08 22:50:50 |
Czytaj oryginał (ang.) |
| Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 |
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. |
globenewswire.com |
2024-08-01 13:00:00 |
Czytaj oryginał (ang.) |
| Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction |
– Transaction aligns with Coherus' strategic focus on oncology – – Transaction aligns with Coherus' strategic focus on oncology – |
globenewswire.com |
2024-06-27 12:26:00 |
Czytaj oryginał (ang.) |
| Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference |
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 8:30 a.m. Eastern Daylight Time / 5:30 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until July 7, 2024. |
globenewswire.com |
2024-05-30 13:00:00 |
Czytaj oryginał (ang.) |
| Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting |
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors |
globenewswire.com |
2024-05-23 21:51:00 |
Czytaj oryginał (ang.) |
| Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA |
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA on Wednesday, May 29, 2024 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time. The presentation will be accessible via Webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations. This webcast will be available for replay until June 26, 2024. |
globenewswire.com |
2024-05-23 13:00:00 |
Czytaj oryginał (ang.) |
| Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript |
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Denny Lanfear - Chief Executive Officer Paul Reider - Chief Commercial Officer Rosh Dias - Chief Medical Officer Theresa LaVallee - Chief Development Officer Bryan McMichael - Interim Chief Financial Officer Conference Call Participants Michael Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Colleen Kusy - Baird Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-05-10 04:07:07 |
Czytaj oryginał (ang.) |
| Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates |
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.75 per share a year ago. |
zacks.com |
2024-05-09 22:16:07 |
Czytaj oryginał (ang.) |
| Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update |
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif. |
globenewswire.com |
2024-05-09 20:01:00 |
Czytaj oryginał (ang.) |
| Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan |
– New $38.7 million term loan with a May 2029 maturity – – $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® – |
globenewswire.com |
2024-05-09 11:30:00 |
Czytaj oryginał (ang.) |
| Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer |
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the iPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers. |
globenewswire.com |
2024-05-08 13:00:00 |
Czytaj oryginał (ang.) |